Swiss National Bank Has $5.72 Million Stock Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Swiss National Bank trimmed its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 9.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 177,550 shares of the biopharmaceutical company’s stock after selling 18,300 shares during the quarter. Swiss National Bank owned approximately 0.21% of Revance Therapeutics worth $5,719,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Commonwealth Equity Services LLC grew its stake in shares of Revance Therapeutics by 17.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 88,819 shares of the biopharmaceutical company’s stock valued at $1,639,000 after buying an additional 12,994 shares in the last quarter. Integral Health Asset Management LLC increased its stake in shares of Revance Therapeutics by 4.2% during the 1st quarter. Integral Health Asset Management LLC now owns 250,000 shares of the biopharmaceutical company’s stock worth $8,052,000 after purchasing an additional 10,000 shares during the last quarter. Blair William & Co. IL raised its holdings in shares of Revance Therapeutics by 13.8% in the 4th quarter. Blair William & Co. IL now owns 125,505 shares of the biopharmaceutical company’s stock valued at $2,317,000 after purchasing an additional 15,200 shares during the period. Yarbrough Capital LLC acquired a new stake in Revance Therapeutics in the 1st quarter valued at about $393,000. Finally, Picton Mahoney Asset Management grew its holdings in Revance Therapeutics by 62.8% during the fourth quarter. Picton Mahoney Asset Management now owns 99,980 shares of the biopharmaceutical company’s stock worth $1,844,000 after purchasing an additional 38,580 shares during the period. Institutional investors and hedge funds own 93.28% of the company’s stock.

Insider Activity

In related news, Director Carey Oconnor Kolaja sold 2,500 shares of the stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $28.24, for a total value of $70,600.00. Following the completion of the sale, the director now directly owns 16,561 shares in the company, valued at $467,682.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Carey Oconnor Kolaja sold 2,500 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $28.24, for a total value of $70,600.00. Following the transaction, the director now owns 16,561 shares in the company, valued at approximately $467,682.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Mark J. Foley sold 26,279 shares of the stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $22.57, for a total value of $593,117.03. Following the sale, the chief executive officer now owns 840,375 shares of the company’s stock, valued at $18,967,263.75. The disclosure for this sale can be found here. Over the last three months, insiders have sold 95,739 shares of company stock valued at $2,559,269. 3.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have recently issued reports on RVNC. BNP Paribas raised Revance Therapeutics from an “underperform” rating to a “neutral” rating and set a $20.00 price objective for the company in a research report on Wednesday, August 16th. Morgan Stanley decreased their price objective on shares of Revance Therapeutics from $26.00 to $25.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 9th. StockNews.com began coverage on shares of Revance Therapeutics in a research note on Thursday, August 17th. They set a “hold” rating for the company. Piper Sandler upped their price target on shares of Revance Therapeutics from $39.00 to $50.00 in a research note on Wednesday, May 10th. Finally, Needham & Company LLC cut their price objective on shares of Revance Therapeutics from $44.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday, August 9th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Revance Therapeutics Stock Down 0.1 %

Shares of RVNC opened at $18.27 on Wednesday. The company has a debt-to-equity ratio of 14.20, a current ratio of 5.12 and a quick ratio of 4.65. Revance Therapeutics, Inc. has a one year low of $16.93 and a one year high of $37.98. The company has a market cap of $1.61 billion, a P/E ratio of -4.03 and a beta of 0.75. The firm has a 50 day simple moving average of $22.25 and a two-hundred day simple moving average of $28.57.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Revance Therapeutics had a negative net margin of 191.93% and a negative return on equity of 903.28%. The company had revenue of $58.13 million during the quarter, compared to the consensus estimate of $58.71 million. During the same period in the previous year, the company earned ($0.88) EPS. Revance Therapeutics’s revenue for the quarter was up 104.9% on a year-over-year basis. Research analysts forecast that Revance Therapeutics, Inc. will post -2.8 EPS for the current fiscal year.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.